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Abstract
Next generation sequencing technology has revolutionized the study of cancers. Through matched normal-tumor pairs, it is
now possible to identify genome-wide germline and somatic mutations. The generation and analysis of the data requires
rigorous quality checks and filtering, and the current analytical pipeline is constantly undergoing improvements. We noted
however that in analyzing matched pairs, there is an implicit assumption that the sequenced data are matched, without any
quality check such as those implemented in association studies. There are serious implications in this assumption as
identification of germline and rare somatic variants depend on the normal sample being the matched pair. Using a genetics
concept on measuring relatedness between individuals, we demonstrate that the matchedness of tumor pairs can be
quantified and should be included as part of a quality protocol in analysis of sequenced data. Despite the mutation changes
in cancer samples, matched tumor-normal pairs are still relatively similar in sequence compared to non-matched pairs. We
demonstrate that the approach can be used to assess the mutation landscape between individuals.
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Introduction
Mutations are hallmark of cancers and identification of the
mutations is imperative in our understanding of the disease. The
advance in next generation sequencing (NGS) has transformed the
way to identify mutations, just like microarray did a decade ago.
Currently, the technology offers a powerful and yet relatively cost
effective approach to characterize genome-wide mutations that
occur in diseases. It enables identification of somatic mutations,
including base substitutions, indels, chromosomal rearrangements,
copy number alterations, and transcriptional aberrations. The
rapid increase in NGS publications recently illustrated the
potential of the technology, reporting rare mutations in various
cancers, many previously undetected [1,2,3,4,5,6,7]. In some of
the studies, matched normal-tumor pairs were utilized to identify
germline and rare somatic mutations [4,6,7], while in other
studies, matched tumor-tumor (e.g. primary versus metastatic)
were used [1]. While the approach in NGS has been rigorous in
the generation of data as well as analysis, we note that there is a
lack of quality check to assess if the matched normal-tumor pair
was indeed matched. Since identification of germline and de novo
rare somatic mutations relies on the matched normal sample, there
is necessity to perform quality check on the sequenced data, to
ensure the basis of the assumption is upheld. Relatedness check is
an essential procedure in linkage and association studies to prevent
sample mislabeling or misspecification of relationships between
DNA samples which can lead to spurious or biased results [8,9]. As
most of the NGS studies so far involve only one matched pair
[3,6,7], it would thus seem trivial to check for relatedness. There is
however a growing trend towards sequencing large number of
samples [4], and given the anticipation that the cost for NGS will
drop further, it will soon be possible to do so. It is thus timely to
consider relatedness checks and incorporate it as a quality control
protocol for NGS analysis.
We propose here, a simple method using the concept of identity-
by-state (IBS), an allele sharing approach used in genetics study to
verify matched pairs. IBS is often used in single nucleotide
polymorphism (SNP) data to ascertain relationship between
individuals in the absence of pedigree structure [10]. It measures
the degree to which related individuals share alleles and is often
used to map complex traits in human relative pairs. Besides
relatedness, IBS can also identify meiotic crossovers, and other
broad range of chromosomal anomalies such as hemizygous
deletions, and uniparental disomy, as well as population structure
in families [11]. As IBS has been traditionally used in genetics
studies to identify variants in populations, it is thus novel to apply
the idea in cancer samples, especially in this particular context of
assessing matched normal-tumor pairs. Using IBS on two datasets
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that clustering of matched normal-tumor samples can be used to
assess the ‘matchedness’ of pairs. We also show how IBS can be
used to reveal the diversity and occurrence of mutation across the
samples.
Results and Discussion
Two datasets were used in the study; 82 matched pairs on SNP6
and 7 pairs sequenced using NGS (see Methods). Five matched
pairs were common in SNP6 and NGS. As IBS is traditionally
used in SNP data, we included SNP6 as a validation for the
approach.
Matched and unmatched pairs are clustered differentially
Figure 1 showed the clustering of SNP6 and NGS data in the
IBS-space which is based on the mean and variance of IBS
between two samples. For each dataset, the matched pairs were
differentially clustered from the unmatched pairs, and the matched
pairs tend to be clustered in the bottom-right corner. This is
expected since the relationship of matched samples can be likened
to replicates or monozygotic twins, where both alleles are similar.
In this scenario, IBS distribution should exhibit a mean near to 2
and with small variance. The basis of this assumption is supported
by several studies indicating somatic mutation rate in cancers
varies from 1.8 to 3.9 per Mb [2,12], suggesting that matched pairs
will exhibit sufficient ‘replicate-like’ characteristics for differential
clustering in IBS. As evident in the clustering of Figure 1, matched
pairs were clustered together and further from the unmatched
pairs, indicating the differences in the relatedness between the
samples. The differential clustering in IBS-space can thus be used
to infer matchedness of samples. In this case, it showed that all the
samples in both datasets were matched.
From both the SNP6 and NGS data, we observed that although
there is differential clustering between the matched and
unmatched pairs, the relative position in both data differed
slightly. In the ‘NGS & SNP6 matched’ cluster (Figure 1), SNP6
data showed higher IBS mean and lower IBS variance, indicating
that mutations in common variants was relatively less compared to
NGS, an observation in line with the understanding that SNPs in
the Affymetrix SNP 6.0 chip were supposedly well validated
common polymorphisms. It is of note that NGS nucleotides were
reference variants including dbSNP and novel single nucleotide
variants (SNV) targeted mostly at exons (see Methods). As there is
uneven distribution of mutation across the genome, with lower
prevalence observed in gene regions [7], the level of similarity
observed in NGS may be an under estimation of mutations in the
samples. Nevertheless, even with the limited exome sequence of
Figure 1. IBS clustering of SNP6 (green) and NGS (blue) samples. IBS for each pair of samples is computed and the mean (x-axis) and variance
(y-axis) plotted in the IBS-space. Matched (denoted as *) and unmatched pairs (denoted as +) are clustered differentially where the matched pairs are
positioned towards the bottom-right corner indicating more relatedness between samples. 5 SNP6 samples (red) were also sequenced in NGS. One of
the samples, 76629543, is clustered further away from the bottom right in both datasets, indicating its higher level of mutations.
doi:10.1371/journal.pone.0017810.g001
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can be differentiated using IBS.
Another interesting aspect of the IBS clustering is the range in
which matched pairs were spread across a spectrum. For example,
sample 76629543 was clustered further away from the other
matched samples and bottom right corner. The spread of data
points within each cluster indicated the degree of relatedness
which may be useful in assessing tumor content. Intuitively,
matched samples that are further away from bottom-right would
suggest more mutations in the tumor samples. This is also
dependent on the quality of the normal samples. We devised a
simple IBSmv score (IBSmean/IBSvar) and ranked it against tumor
content assessed by pathologist (see Table S1). Using an arbitrary
IBSmv of 430 as a cut-off on the SNP6 data, the Wilcoxon test on
the distribution of tumor content between the low and high IBSmv
groups was 0.0081, indicating that low IBSmv was associated with
higher tumor content. The result is indicative but needs to be
further validated. Along the same line of thought, IBS can be a
means to select samples for sequencing; such as choosing those
that are likely to exhibit more mutations, i.e. samples with lower
IBSmv. This is useful for samples with available SNP data, where
IBS can provide a quick analysis to assess the level of mutation.
Distribution of IBS across genome for matched pairs
reveals the mutation landscape
Figure 2 showed the IBS of 2 matched pairs (samples 76629543
and 2000619) in NGS across the genome. (For IBS landscape of all
7 matched pairs, see Figure S1.) It revealed the distribution of IBS
across the samples, where IBS of 0, 1, and 2 were denoted as IBS-
0, IBS-1, and IBS-2 (see Methods). Most of the IBS were IBS-2 as
shown by the green ticks in the figure, indicating that both alleles
between matched normal and tumor were similar. The frequency
of IBS-1 and IBS-0 varied amongst the samples, ranging from 1.2
to 15% (out of all SNVs for each matched tumor-normal pair).
Sample 76629543 had the most allele changes in chr8, 10, 11, 12,
17, 19, and 22q, and was the sample clustered furthest away from
the matched pairs cluster (Figure 1). The diversity in its IBS
landscape was in concordance with its low IBSmv. Table 1
summarized the frequency of IBS in the 7 NGS samples. Most of
the changes were IBS-1 which were heterozygous variants; i.e.
AA/BB-.AB (somatic) or AB-.AA/BB (LOH). Frequency of
LOH varied from 37.4% to 90.6%. Homozygous variant (i.e. IBS-
0, AA-.BB) on the other hand was not common, occurring less
than 2% of all IBS-1 and IBS-0, mostly in dbSNP. Of the 7
samples, more than 3 samples had IBS-0 or IBS-1 in chr6 (HLA-
A, HLA-B, HLA-C), chr10 (FANK1, TUBGCP2), chr17
(CDC27), and chr22 (CYP2D6). There were 53 IBS-0 of which
2 samples has IBS-0 in ADAMTS9. The most IBS-1 for LOH was
found in KIR3DP1 and RYR1 (2 samples with 15 LOH each).
Detailed analysis of the variants is still in progress and will be
reported elsewhere.
Conclusion
One of the underlying assumptions in this approach is the
relatively low mutation rate in cancer. This was shown by our own
NGS study on gastric cancer kinome [13] as well as others who
looked at a broad range of tumors. Although it is known implicitly
that mutations are a hallmark of cancers, we have not yet
quantified the similarity or dissimilarity between a cancer genome
and the matched normal. Surprisingly, the difference is relatively
small, such that non-matched samples, whether between normal
or tumors, are still considerably more different than matched
normal-tumor. In this paper, we demonstrated that clustering in
IBS-space provides a robust quantitative approach to assess
Figure 2. IBS landscape of samples 76629543 and 2000619 in NGS. For each chromosome, the different states of IBS is shown (green: IBS-2,
red: IBS-1, black: IBS-0). Sample ID is indicated at the top of each genome plot. Most of the alleles do not change state between matched pairs, i.e.
IBS-2 (green). The most frequent allele change is IBS-1 or heterozygous variant (red). IBS-0 or homozygous variant (black) is not common, occurring
less than 2%. Sample 76629543 shows the most varied IBS in chr8, 10, 11, 12, 17, 19, and 22q.
doi:10.1371/journal.pone.0017810.g002
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to assess tumor content as well as selection of samples for
sequencing using SNP data. In addition, the IBS landscape offers a
genomic view of the mutation across the samples. As shown, the
mutations were mostly heterozygous somatic or LOH. Homozy-
gous variants were less common and most found in this study were
in dbSNP.
Methods
Primary and matched gastric tissues were obtained from the
Singhealth Tissue Repository, after approvals from Institutional
Research Ethics Review Committees, and with signed patient
informed consent. Samples were isolated from patients and
characterized by pathology. Tumor content information was
available for 22/82 samples in SNP6 and 1/7 in NGS (see Table
S1).
SNP6
Genomic DNA was hybridized to the Affymetrix SNP 6.0
chip, following the manufacturer’s instructions. The raw data
was normalized with normal as controls using Affymetrix
Genotyping Console. 82 matched samples were available for
this study. To maintain compatibility with NGS dataset, 30K
SNPs were selected randomly across the 22 autosomes to
generate the SNP6 dataset. To check for bias in the selection of
SNPs, several SNP data consisting of 20K and 25K randomly
selected SNPs were generated and the IBS computed using our
algorithm and the visual tool graphical relationship represen-
tation (GRR) [10] (see Figure S2). GRR is a visual tool using
IBS to assess relatedness in pedigree. IBS was also computed for
the entire SNP dataset (see Figure S3). The plots showed similar
clustering regardless of number of SNPs. The genetic tool Plink
[14] was used to generate the various SNP datasets in this
study.
NGS
Seven matched pairs (5 from the 82 samples in SNP6) were
sequenced using array-based sequence capture (Agilent SureSe-
lect) and Illumina GAIIx sequencer, targeting mostly the exons.
The data was put through our sequencing pipeline consisting of
base calling using the Illumina Pipeline, mapping and alignment
with BWA [15], PCR duplication removal with SAMTools [16],
and GATK [17] for variants calling. To incorporate the
matchedness check as a quality control, we analyzed all the
variants from reference sequence (dbSNP and novel) output from
GATK with consensus quality $30, read depth $5, and variant
depth $2. On average, there are 24857 SNVs per sample, 24427
SNVs between matched pairs and 32286 SNVs between
unmatched pairs. For comparison, GRR was also used to assess
the IBS clustering (see Figure S4).
IBS computation
Any two individuals (or samples), whether related or not, can
share 0, 1, or 2 alleles, denoted as IBS-0 (both alleles are different),
IBS-1 (one of the allele is different), and IBS-2 (both alleles are the
same) respectively. Alleles in the dataset were coded using A and B
and pairwise IBS was computed between all samples. See Table 2
for the possible scenarios between samples’ alleles and IBS score.
Display of the IBS landscape was done using GenomeRelator
(http://www.chromosomechronicles.com/2009/10/22/identity-by-
state-snp-analysis-find-relatives-test-paternity-and-determine-
allele-sharing/). The R code for IBS computation is available
at http://research.duke-nus.edu.sg/papers/IBS.zip.
Supporting Information
Figure S1 IBS landscape of 7 matched pairs in NGS.
(TIF)
Figure S2 Comparison of IBS for 20K, 25K, and 30K
SNPs using our algorithm (left) and GRR (right). Note
that GRR shows standard deviation (y-axis) instead of variance.
Clustering in both plots is similar regardless of the number of SNPs
indicating that there is no bias and a smaller set of SNPs would
suffice for assessing matched tumor-normal pairs.
(TIF)
Figure S3 IBS plot of all 868155 SNPs. The clustering is
similar to the datasets of 20K, 25K, and 30K SNPs indicating
that the clustering is not bias by number of SNPs. Note that this
computation was not possible with GRR and IBS computa-
tion for entire SNP dataset can be intensive even with our
algorithm.
(TIF)
Figure S4 IBS plot using GRR showed similar cluster-
ing. Note that y-axis is standard deviation instead of
variance in the manuscript.
(TIF)
Table S1 IBS scores and tumor content for the 22 samples in
SNP6 data.
*Sample 76629543 was sequenced (NGS) and profiled
for SNP6.
(XLSX)
Table 1. IBS-0 and IBS-1 (somatic and LOH) frequency
summary of the NGS samples.
Sample
AA/BB-.AB
(Somatic, IBS-1)
AB-.AA/BB
(LOH, IBS-1)
AA-.BB
(IBS-0) Total
990172 151 (50.84) 143 (48.15) 3 (1.01) 297
990300 311 (57.06) 224 (41.1) 10 (1.83) 545
990355 203 (61.7) 123 (37.39) 3 (0.91) 329
990475 170 (50.6) 163 (48.51) 3 (0.89) 336
2000619 220 (29.69) 515 (69.5) 6 (0.81) 741
2000778 260 (56.03) 201 (43.32) 3 (0.65) 464
76629543 318 (8.76) 3287 (90.55) 25 (0.69) 3630
Percentages are indicated in parenthesis.
doi:10.1371/journal.pone.0017810.t001
Table 2. IBS scores between samples.
Sample 1 Sample 2 IBS
AA AA 2
AA AB 1
AA BB 0
AB AB 2
AB BB 1
BB BB 2
doi:10.1371/journal.pone.0017810.t002
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